Biogen has taken Anabella Villalobos, Ph.D., away from Pfizer and placed her as its new SVP of biotherapeutic and medicinal sciences.
With her new role and team, Villalobos will lead Biogen’s BTMS organization in the delivery of “high-quality, differentiated molecules” to the clinic, according to a statement. She will report to Michael Ehlers, M.D., Ph.D., the Big Biotech’s head of R&D.
“We are excited to have Anabella Villalobos join us at Biogen,” said Ehlers. “Anabella is a world-class drug hunter, a proven leader in medicinal sciences, and a champion of scientific innovation. Her experience in neuroscience and passion for drug discovery will help us create and advance the next generation of breakthrough medicines.”
Villalobos comes to Biogen from Pfizer worldwide research and development, most recently being the Big Pharma’s VP and head of medicinal synthesis technologies.
She’s been in the industry for 25 years, spending much of her career working in areas of neuroscience and medicinal chemistry, and on clinical candidates for Alzheimer’s disease, Parkinson’s disease, schizophrenia and pain.
CNS is becoming the biggest focus of Biogen’s pipeline, with much hope being rested on its Alzheimer’s candidate aducanumab, which has seen both positives and negatives in recent read-outs, and will need to buck the terrible trend of Alzheimer’s R&D in recent years, which has seen a near 99% failure rate.
In its financials last week, it also announced that it “intends to remain focused on neuroscience and adjacencies,” which could include deals in these areas. The specific aim is to bolster its pipeline, while also streamlining some ops to allocate more to R&D, with $400 million on the table for this operation.
“Biogen has been an absolute pacesetter in developing breakthrough neurology medicines in the form of biologics, small molecules and new anti-sense oligonucleotide therapies for patients.” said Villalobos.
“I am honored to lead Biotherapeutic & Medicinal Sciences, and I look forward to accelerating our neuroscience discovery to find new approaches for the most challenging conditions of the brain.”
By Ben Adams
Source: FierceBiotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
